GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » EV-to-FCF

TME Pharma NV (XPAR:ALTME) EV-to-FCF : -1.11 (As of May. 21, 2024)


View and export this data going back to 2016. Start your Free Trial

What is TME Pharma NV EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, TME Pharma NV's Enterprise Value is €6.29 Mil. TME Pharma NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-5.65 Mil. Therefore, TME Pharma NV's EV-to-FCF for today is -1.11.

The historical rank and industry rank for TME Pharma NV's EV-to-FCF or its related term are showing as below:

XPAR:ALTME' s EV-to-FCF Range Over the Past 10 Years
Min: -3.72   Med: 0.18   Max: 0.26
Current: -1.08

During the past 10 years, the highest EV-to-FCF of TME Pharma NV was 0.26. The lowest was -3.72. And the median was 0.18.

XPAR:ALTME's EV-to-FCF is ranked worse than
100% of 379 companies
in the Biotechnology industry
Industry Median: 8.34 vs XPAR:ALTME: -1.08

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-21), TME Pharma NV's stock price is €0.259. TME Pharma NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.340. Therefore, TME Pharma NV's PE Ratio for today is At Loss.


TME Pharma NV EV-to-FCF Historical Data

The historical data trend for TME Pharma NV's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV EV-to-FCF Chart

TME Pharma NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.47 -3.18 -0.84 -0.13 -0.51

TME Pharma NV Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.84 - -0.13 - -0.51

Competitive Comparison of TME Pharma NV's EV-to-FCF

For the Biotechnology subindustry, TME Pharma NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TME Pharma NV's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TME Pharma NV's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where TME Pharma NV's EV-to-FCF falls into.



TME Pharma NV EV-to-FCF Calculation

TME Pharma NV's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=6.287/-5.654
=-1.11

TME Pharma NV's current Enterprise Value is €6.29 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TME Pharma NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-5.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TME Pharma NV  (XPAR:ALTME) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

TME Pharma NV's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.259/-1.340
=At Loss

TME Pharma NV's share price for today is €0.259.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TME Pharma NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.340.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


TME Pharma NV EV-to-FCF Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


TME Pharma NV (XPAR:ALTME) Business Description

Traded in Other Exchanges
Address
Max-Dohrn-Street 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product candidates are; NOX-A12 and NOX-E36 are based on a new class of drug first developed by TME Pharma called Spiegelmers, which offer specific advantages over other drug classes.

TME Pharma NV (XPAR:ALTME) Headlines

No Headlines